Selective AKR1C3 Inhibitors Potentiate Chemotherapeutic Activity in Multiple Acute Myeloid Leukemia (AML) Cell Lines

Area of Science:

• Medicinal Chemistry
• Oncology
• Biochemistry

Background:

• Aldo-keto reductase 1C3 (AKR1C3) is a key enzyme regulating myeloid cell processes like proliferation and apoptosis.
• Dysregulation of AKR1C3 is implicated in myeloid malignancies, including acute myeloid leukemia (AML).

Purpose of the Study:

• To design, synthesize, and evaluate novel, potent, and selective inhibitors of AKR1C3.
• To assess the therapeutic potential of AKR1C3 inhibitors as an adjuvant therapy in combination with standard chemotherapeutics for AML.

Main Methods:

• Synthesis and in vitro evaluation of novel AKR1C3 inhibitors.
• Combination treatment studies using AKR1C3 inhibitors with etoposide or daunorubicin in AML cell lines.

Main Results:

• The developed AKR1C3 inhibitors demonstrated potent and selective activity.
• Combination therapy significantly potentiated the cytotoxicity of etoposide (up to 6.25-fold) and daunorubicin (over 10-fold) in AML cell lines.
• AKR1C3 inhibition was validated as a common adjuvant target across diverse AML subtypes.

Conclusions:

• AKR1C3 inhibitors show promise as effective adjuvant agents in AML therapy.
• Co-administration with chemotherapeutics may enhance the therapeutic index, potentially expanding treatment options for pediatric and geriatric patients by mitigating side effects.